This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress
by Kinjel Shah
AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Sanofi, Glaxo Start Clinical Study on Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and Glaxo have a collaboration to develop an adjuvant vaccine against coronavirus.
The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK
Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology have a collaboration to develop antibody therapies for treating COVID-19.
Market Waits for Major Economic Data This Week
by Zacks Equity Research
Market Waits for Major Economic Data This Week.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
Big Week of Econ Data Starts on a Lull
by Mark Vickery
Although this will be a big week for economic data, today sees nothing new on this front.
Top Analyst Reports for Salesforce, Merck & AT&T
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Merck Co. (MRK) and AT&T (T).
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo
by Zacks Equity Research
Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.
Glaxo Receives EU Approval for Multiple Myeloma Drug Blenrep
by Zacks Equity Research
The European Commission lends a nod to Glaxo's (GSK) Blenrep as a monotherapy for patients with relapsed/refractory multiple myeloma, having received at least four previous therapies.
Merck's Keytruda Gets Approval for Esophageal Cancer in Japan
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.
FDA Nods to Novartis' Kesimpta for Relapsing Forms of MS
by Zacks Equity Research
Novartis (NVS) gains an FDA nod for Kesimpta (ofatumumab) as a subcutaneous injection for relapsing multiple sclerosis. The drug is expected to be available early next month.
Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
Glaxo Initiates Dosing in Phase III Meningitis Vaccine Study
by Zacks Equity Research
Glaxo (GSK) starts dosing with a phase III study on it 5-in-1 meningitis vaccine candidate.
Merck's Keytruda Positive in First-Line Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.
FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension
by Zacks Equity Research
Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.